ZSNeo-DC1.1 / Zhongsheng Kangyuan Biotech - LARVOL DELTA

Phase I clinical trial of personalized dendritic cell injection ZSNeo-DC1.1 in the treatment of malignant solid tumors (ChiCTR) - P1 | N=12 | Completed | Sponsor: Chinese People's Liberation Army General Hospital; Zhongsheng Kangyuan Biotechnology (Beijing) Co., LTD

New P1 trial • Solid Tumor

ZSKY2023-1002: Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Beijing Tiantan Hospital | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Beijing Tiantan Hospital

New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor